Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Glatiramer acetate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    72 result(s) found for: Glatiramer acetate. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2006-004893-29 Sponsor Protocol Number: PDY6046 Start Date*: 2007-07-25
    Sponsor Name:Sanofi-aventis U.S. Inc.
    Full Title: A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide...
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011088-35 Sponsor Protocol Number: PACAMUS Start Date*: 2010-03-24
    Sponsor Name:Philipps-Universität Marburg
    Full Title: Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAM...
    Medical condition: Patients with Multiple Sclerosis (MS) or Clinically isolated syndrome suggestive for MS (CIS) are investigated. The main objective is to conserve data about changes in the VIP/PACAP (vasoactive int...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015556-15 Sponsor Protocol Number: 101MS325 Start Date*: 2010-05-07
    Sponsor Name:Biogen Idec Limited
    Full Title: A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) PT (Completed) HU (Prematurely Ended) NL (Prematurely Ended) SI (Prematurely Ended) LV (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004903-39 Sponsor Protocol Number: WCNNMBJR001 Start Date*: 2005-07-26
    Sponsor Name:The Walton Centre for Neurology and Neurosurgery
    Full Title: A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis.
    Medical condition: Early, active relapsing remitting Multiple Sclerosis (RRMS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006323-39 Sponsor Protocol Number: SuniMS-03 Start Date*: 2007-06-19
    Sponsor Name:Charité-Universitätsmedizin Berlin
    Full Title: Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis
    Medical condition: relapsing-remitting multiple sclerosis ICD classification: G35.1
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000462-13 Sponsor Protocol Number: GA/7025 Start Date*: 2004-07-12
    Sponsor Name:TEVA Pharmaceutical Industries Ltd.
    Full Title: A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 300mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (...
    Medical condition: Relapsing-remitting multiple sclerosis (R-R MS)
    Disease: Version SOC Term Classification Code Term Level
    5.1 10028245 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000463-94 Sponsor Protocol Number: GA/7026 Start Date*: 2007-07-03
    Sponsor Name:TEVA Pharmaceutical Industries Ltd.
    Full Title: A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 600mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (...
    Medical condition: Relapsing-remitting multiple sclerosis (R-R MS)
    Disease: Version SOC Term Classification Code Term Level
    5.1 10028245 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-018084-27 Sponsor Protocol Number: MS-GA-301 Start Date*: 2010-03-30
    Sponsor Name:Teva Pharmaceutical Industries, Ltd.
    Full Title: A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer...
    Medical condition: Relapsing-remitting Multiple Sclerosis (RR MS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) EE (Completed) CZ (Completed) LT (Completed) BG (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005550-57 Sponsor Protocol Number: GA-MS-302 Start Date*: 2012-05-15
    Sponsor Name:Teva Pharmaceutical Industries Ltd.
    Full Title: A multinational, multicenter, randomized, parallel group, double blind, placebo controlled study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, saf...
    Medical condition: Relapsing-remitting Multiple sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) EE (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003997-24 Sponsor Protocol Number: LTS 6047 Start Date*: 2008-07-08
    Sponsor Name:Sanofi-Aventis recherche & développement
    Full Title: Long-term extension of the multinational, double-blind, placebo controlled study PDY6045 and PDY6046 to document the safety of teriflunomide when added to treatment with interferon-beta or glatiram...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000284-93 Sponsor Protocol Number: Mapi_GADepotPhaseIII-001 Start Date*: 2019-12-10
    Sponsor Name:Mapi Pharma Ltd.
    Full Title: A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing forms of Multiple Sclerosis (RMS) to assess the efficacy, safe...
    Medical condition: Relapsing forms of Multiple Sclerosis (RMS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000888-27 Sponsor Protocol Number: GTR001 Start Date*: 2011-09-21
    Sponsor Name:Synthon BV
    Full Title: Multi-centre, randomized, double-blind, placebo-controlled, parallel-group, 9 month, equivalence trial comparing the efficacy and safety and tolerability of GTR (Synthon BV) to Copaxone® (Teva) in ...
    Medical condition: Relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) GB (Completed) DE (Completed) EE (Completed) GR (Prematurely Ended) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-000922-12 Sponsor Protocol Number: TV44400-CNS-40083 Start Date*: 2016-01-04
    Sponsor Name:Teva Pharmaceutical Industries, Ltd
    Full Title: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous...
    Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) IE (Completed) PL (Completed) FI (Completed) ES (Completed) HR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002037-20 Sponsor Protocol Number: GA/9016 Start Date*: 2006-07-27
    Sponsor Name:Teva Pharmaceutical Industries, Ltd.
    Full Title: A multi-national, multi-centre, randomized, parallel-group, double-blind study to compare the efficacy, tolerability and safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetat...
    Medical condition: Relapsing-remitting Multiple Sclerosis (RR MS)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028245 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) BE (Completed) GB (Prematurely Ended) LV (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended) LT (Prematurely Ended) DE (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010661-23 Sponsor Protocol Number: 2009-010661-23 Start Date*: 2009-07-30
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI
    Full Title: MITOXANTRONE/GLATIRAMER ACETATE COMBINED TREATMENT IN THE THERAPY OF SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS
    Medical condition: subjects affected by secondary-progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029205 SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-005129-18 Sponsor Protocol Number: PROMISE Start Date*: 2019-01-08
    Sponsor Name:Università degli Studi Aldo Moro
    Full Title: Multi-centre, randomised, open label pragmatic trial to compare the effectiveness and safety of interferon beta-1a (IFN-beta-1a) weekly i.m. and glatiramer-acetate (GA) in paediatric patients affec...
    Medical condition: Relapsing-remitting multiple sclerosis with paediatric onset
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002283-25 Sponsor Protocol Number: EMR200575-001 Start Date*: 2013-12-18
    Sponsor Name:Merck KGaA
    Full Title: A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study To Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copax...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) IT (Completed) GB (Completed) FI (Completed) GR (Completed) ES (Completed) BG (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2006-001688-49 Sponsor Protocol Number: ALS-GA-201 Start Date*: 2006-08-14
    Sponsor Name:TEVA Pharmaceutical Industries. Ltd.
    Full Title: A multi-national, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, tolerability and safety of 40 mg glatiramer acetate injection in subjects ...
    Medical condition: Early stage of amyotrophic lateral sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10002026 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004505-32 Sponsor Protocol Number: COMB157G3301 Start Date*: 2021-06-09
    Sponsor Name:Novartis Pharma AG
    Full Title: An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT-physician’s choi...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-013129-41 Sponsor Protocol Number: OCT15-05-09 Start Date*: 2009-07-20
    Sponsor Name:Amphia Ziekenhuis
    Full Title: A multicenter open label randomized pilot study, to compare retinal nerve fiber layer thickness measured by Optical Coherence Tomography after treatment with daily 20 mg glatiramer acetate subcutan...
    Medical condition: clinical isolated syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028248 Multiple sclerosis-like syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 01:58:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA